GT516 / Geneuintech, Afrigen Biologics & Vaccines - LARVOL DELTA

Gimhae Genyuintech developed ‘multifunctional cancer treatment (Afrigen Biologics & Vaccines Press Release) - "A company in Gimhae has developed a cell therapy product (GT516. anti DR4 CAR-TI that can be applied to ‘solid tumors’ beyond the existing cell therapy (CD19 CAR-T), which was applied only to blood cancer....CAR-T therapy is a new concept of anticancer drug that combines immune ‘T cells’ and ‘gene manipulation’ technologies. Gimhae Biomedical & Industry Promotion Agency announced on the 12th that Genu lntech Co., Ltd. signed a MOU with South Africa’s ‘Afrigen Biologics & Vaccines’ in September related to CAR-T technology for anti-cancer cell therapy. The main content of the agreement is to jointly carry out and commercialize the technologies and procedures necessary for the launch of new drugs, such as clinical trials for human subjects of therapeutics developed by Genu lntech Co., Ltd. The treatment can be launched as soon as it passes a 'phase 2 clinical trial' to test its 'efficacy.'"

Licensing / partnership • Oncology • Solid Tumor